These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32848385)

  • 21. Blood-brain barrier and blood-brain tumor barrier penetrating peptide-drug conjugate as targeted therapy for the treatment of lung cancer brain metastasis.
    Zheng MZ; Yang ZQ; Cai SL; Zheng LT; Xue Y; Chen L; Lin J
    Lung Cancer; 2024 Oct; 196():107957. PubMed ID: 39303402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
    White MN; Piotrowska Z; Stirling K; Liu SV; Banwait MK; Cunanan K; Sequist LV; Wakelee HA; Hausrath D; Neal JW
    Clin Lung Cancer; 2021 May; 22(3):201-209. PubMed ID: 33610453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prodrug Delivery Using Dual-Targeting Nanoparticles To Treat Breast Cancer Brain Metastases.
    Ju X; Chen H; Miao T; Ni J; Han L
    Mol Pharm; 2021 Jul; 18(7):2694-2702. PubMed ID: 34109794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals.
    Zong T; Mei L; Gao H; Cai W; Zhu P; Shi K; Chen J; Wang Y; Gao F; He Q
    Mol Pharm; 2014 Jul; 11(7):2346-57. PubMed ID: 24893333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
    Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C
    Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymph cancer chemotherapy: delivery of doxorubicin-gemcitabine prodrug and vincristine by nanostructured lipid carriers.
    Ni S; Qiu L; Zhang G; Zhou H; Han Y
    Int J Nanomedicine; 2017; 12():1565-1576. PubMed ID: 28280326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
    Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A PET study in healthy subjects of brain exposure of
    Varrone A; Varnäs K; Jucaite A; Cselényi Z; Johnström P; Schou M; Vazquez-Romero A; Moein MM; Halldin C; Brown AP; Vishwanathan K; Farde L
    J Cereb Blood Flow Metab; 2020 Apr; 40(4):799-807. PubMed ID: 31006308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
    Zhai X; Li W; Li J; Jia W; Jing W; Tian Y; Xu S; Li Y; Zhu H; Yu J
    Radiat Oncol; 2021 Dec; 16(1):233. PubMed ID: 34865626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apoferritin Nanocage for Brain Targeted Doxorubicin Delivery.
    Chen Z; Zhai M; Xie X; Zhang Y; Ma S; Li Z; Yu F; Zhao B; Zhang M; Yang Y; Mei X
    Mol Pharm; 2017 Sep; 14(9):3087-3097. PubMed ID: 28728419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect.
    Wang Y; Zhang H; Hao J; Li B; Li M; Xiuwen W
    Drug Deliv; 2016 May; 23(4):1398-403. PubMed ID: 26079530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficient antiglioblastoma therapy in mice through doxorubicin-loaded nanomicelles modified using a novel brain-targeted RVG-15 peptide.
    Han M; Xing H; Chen L; Cui M; Zhang Y; Qi L; Jin M; Yang Y; Gao C; Gao Z; Xing X; Huang W
    J Drug Target; 2021 Nov; 29(9):1016-1028. PubMed ID: 33825602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lung Cancer Combination Treatment: Evaluation of the Synergistic Effect of Cisplatin Prodrug, Vinorelbine and Retinoic Acid When Co-Encapsulated in a Multi-Layered Nano-Platform.
    Liang Z; Li J; Zhu B
    Drug Des Devel Ther; 2020; 14():4519-4531. PubMed ID: 33149550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.
    Huang J; Li YM; Massague J; Sicheneder A; Vallera DA; Hall WA
    J Neurooncol; 2012 Sep; 109(2):229-38. PubMed ID: 22696210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment.
    Jarry U; Bostoën M; Pineau R; Chaillot L; Mennessier V; Montagne P; Motte E; Gournay M; Le Goff A; Guillaudeux T; Pedeux R
    BMC Cancer; 2021 May; 21(1):530. PubMed ID: 33971844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic antitumor effects of doxorubicin-loaded carboxymethyl cellulose nanoparticle in combination with endostar for effective treatment of non-small-cell lung cancer.
    Li M; Tang Z; Lin J; Zhang Y; Lv S; Song W; Huang Y; Chen X
    Adv Healthc Mater; 2014 Nov; 3(11):1877-88. PubMed ID: 24846434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A NAG-Guided Nano-Delivery System for Redox- and pH-Triggered Intracellularly Sequential Drug Release in Cancer Cells.
    Liang Y; Zhang J; Tian B; Wu Z; Svirskis D; Han J
    Int J Nanomedicine; 2020; 15():841-855. PubMed ID: 32103941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports.
    Koba T; Kijima T; Takimoto T; Hirata H; Naito Y; Hamaguchi M; Otsuka T; Kuroyama M; Nagatomo I; Takeda Y; Kida H; Kumanogoh A
    Medicine (Baltimore); 2017 Feb; 96(6):e6087. PubMed ID: 28178168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
    Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.